Study Summary
First in humans, exploratory, open-label, single-arm, multicentre, non-competitive, dose escalation study to assess the safety and efficacy of CD1a-CAR T therapy in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL)
Want to learn more about this trial?
Request More InfoInterventions
CD1a-CAR TBIOLOGICAL
Autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express CD1a chimeric antigen receptor administered by intravenous infusion following a dose-escalation approach
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Hospital Clínic | Barcelona | Spain | |
| Hospital Sant Joan de Déu | Barcelona | Spain |